Trials / Completed
CompletedNCT03761901
Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium
REtrospective, obserVational Study to Describe the Treatment Patterns and Outcomes of Epidermal Growth Factor Receptor Mutant (EGFRm) Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Patients in Belgium
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 141 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a retrospective, observational, multicentre study to evaluate treatment patterns and outcomes of patients diagnosed with locally advanced or metastatic EGFRm NSCLC in Belgium
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 1L treatment | chemotherapy, EGFR TKI, immunotherapy, other |
| DRUG | 2L Treatment | Chemotherapy, EGFR TKI, immunotherapy, other |
| DRUG | 3L treatment | chemotherapy, EGFR TKI, immunotherapy, other |
Timeline
- Start date
- 2018-09-21
- Primary completion
- 2019-06-19
- Completion
- 2019-06-19
- First posted
- 2018-12-03
- Last updated
- 2020-05-08
Locations
15 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03761901. Inclusion in this directory is not an endorsement.